(0.51%) 5 214.08 points
(0.85%) 39 388 points
(0.27%) 16 346 points
(0.50%) $79.66
(0.39%) $2.31
(0.53%) $2 352.70
(0.71%) $28.57
(0.22%) $993.00
(-0.30%) $0.927
(-0.43%) $10.84
(-0.23%) $0.798
(0.88%) $92.55
0.27% $ 3.76
@ $3.41
Emitido: 12 feb 2024 @ 14:19
Retorno: 10.26%
Señal anterior: feb 8 - 12:41
Señal anterior:
Retorno: -5.28 %
Live Chart Being Loaded With Signals
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors...
Stats | |
---|---|
Volumen de hoy | 4 112.00 |
Volumen promedio | 38 588.00 |
Capitalización de mercado | 51.55M |
EPS | $0 ( 2024-04-01 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.72 |
ATR14 | $0.0690 (1.84%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-06 | Wesolowski John M | Buy | 25 000 | Stock Option (right to buy Common Stock) |
2024-03-06 | Leahy Emer | Buy | 50 000 | Stock Option (right to buy Common Stock) |
2024-03-06 | Goldberg Mark A | Buy | 50 000 | Stock Option (right to buy Common Stock) |
2024-03-06 | Donovan Daniel | Buy | 50 000 | Stock Option (right to buy Common Stock) |
2024-03-06 | Bender Lewis H | Buy | 464 805 | Stock Option (right to buy Common Stock) |
INSIDER POWER |
---|
57.39 |
Last 23 transactions |
Buy: 803 379 | Sell: 331 500 |
Intensity Therapeutics, Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Intensity Therapeutics, Finanzas
Annual | 2023 |
Ingresos: | $0 |
Beneficio Bruto: | $-147 000 (0.00 %) |
EPS: | $-1.220 |
FY | 2023 |
Ingresos: | $0 |
Beneficio Bruto: | $-147 000 (0.00 %) |
EPS: | $-1.220 |
FY | 2022 |
Ingresos: | $0 |
Beneficio Bruto: | $-179 037 (0.00 %) |
EPS: | $-0.570 |
FY | 2021 |
Ingresos: | $0.00 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-0.439 |
Financial Reports:
No articles found.
Intensity Therapeutics,
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico